The US Centers for Disease Control and Prevention (CDC) reports that its Advisory Committee on Immunization Prevention has voted to recommend the administration of a second dose of varicella (chickenpox) vaccine to children aged four to six, in an effort to further improve protection against the disease.
The advice is based on the results of a controlled study in 2,216 children between the ages of 12 months and 12 years that compared one dose varicella vaccine (Merck & Co's Varivax) to two doses over a 10 year observation period. Analysis of the data showed that a single administration of the vaccine was 94.4% effective, whereas a repeat administration conferred protection in 98.3% of those treated. Over a 10-year period, this translates into a 3.3-fold lower risk of developing chickenpox more than 42 days after vaccination.
Single vaccination not uniformly effective
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze